Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

221 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
HER2-targeted therapy influences CTC status in metastatic breast cancer.
Deutsch TM, Riethdorf S, Fremd C, Feisst M, Nees J, Fischer C, Hartkopf AD, Pantel K, Trumpp A, Schütz F, Schneeweiss A, Wallwiener M. Deutsch TM, et al. Among authors: hartkopf ad. Breast Cancer Res Treat. 2020 Jul;182(1):127-136. doi: 10.1007/s10549-020-05687-2. Epub 2020 May 20. Breast Cancer Res Treat. 2020. PMID: 32436146 Free PMC article.
HER2-positive DTCs/CTCs in breast cancer.
Hartkopf AD, Banys M, Fehm T. Hartkopf AD, et al. Recent Results Cancer Res. 2012;195:203-15. doi: 10.1007/978-3-642-28160-0_19. Recent Results Cancer Res. 2012. PMID: 22527508 Review.
The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer.
Wallwiener M, Hartkopf AD, Baccelli I, Riethdorf S, Schott S, Pantel K, Marmé F, Sohn C, Trumpp A, Rack B, Aktas B, Solomayer EF, Müller V, Janni W, Schneeweiss A, Fehm TN. Wallwiener M, et al. Among authors: hartkopf ad. Breast Cancer Res Treat. 2013 Jan;137(2):503-10. doi: 10.1007/s10549-012-2382-0. Epub 2012 Dec 28. Breast Cancer Res Treat. 2013. PMID: 23271327 Clinical Trial.
The HER2 status of disseminated tumor cells in the bone marrow of early breast cancer patients is independent from primary tumor and predicts higher risk of relapse.
Hartkopf AD, Banys M, Meier-Stiegen F, Hahn M, Röhm C, Hoffmann J, Helms G, Taran FA, Wallwiener M, Walter C, Neubauer H, Wallwiener D, Fehm T. Hartkopf AD, et al. Breast Cancer Res Treat. 2013 Apr;138(2):509-17. doi: 10.1007/s10549-013-2470-9. Epub 2013 Mar 15. Breast Cancer Res Treat. 2013. PMID: 23494674
Circulating tumor cells in breast cancer.
Banys M, Müller V, Melcher C, Aktas B, Kasimir-Bauer S, Hagenbeck C, Hartkopf A, Fehm T. Banys M, et al. Clin Chim Acta. 2013 Aug 23;423:39-45. doi: 10.1016/j.cca.2013.03.029. Epub 2013 Apr 24. Clin Chim Acta. 2013. PMID: 23623805 Review.
221 results